Document is current
Any future updates will be listed below
-
Authors
della Monica, Ciro https://orcid.org/0000-0003-0422-4872
Revell, Victoria
Atzori, Giuseppe
Laban, Rhiannon https://orcid.org/0000-0002-5926-8357
Skene, Simon S. https://orcid.org/0000-0002-7828-3122
Heslegrave, Amanda
Hassanin, Hana
Nilforooshan, Ramin
Zetterberg, Henrik
Dijk, Derk-Jan https://orcid.org/0000-0001-5314-1008
-
Funding
Funding for this research was provided by:
UK Dementia Research Institute
- License Information
-
More Information
Article History
Received: 5 April 2024
Revised: 20 August 2024
Accepted: 30 August 2024
First Online: 13 September 2024
Competing interests
: HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave; has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, and Roche; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). The other authors declare that they have no conflicts of interest related to this research.
